Vantage Point

A document recently crossed my desk that was so seminal I needed to share it with my colleagues through this column.  I can only highlight the big pieces for you and suggest that you read the document yourself.

I would like to send you in the direction of a report by Oxfam, a group whose work is spread around the world but often focuses on healthcare delivery, or rather the absence thereof, to the poor.  The report is titled Investing for Life—Meeting Poor People's Needs for Access to Medicines through Responsible Business Practices.

In this report, Oxfam maintains that one of the major responsibilities of pharma companies is to develop and distribute meds to underdeveloped countries that cannot afford to pay for these agents.  Until now, Oxfam maintains, the industry has provided such access primarily as a PR stunt, i.e., taking already developed medications for diseases such as AIDS/HIV and distributing them to the needy at minimal pricing, thus permitting them to hold forth to the world their humanitarian behavior.  

As underdeveloped countries become more like the developed countries, with low-visibility killers such as hypertension becoming the real problems, Oxfam says that most pharma companies have no plan in place to deliver meds to the poor, let alone develop new products in areas that might only be of use in such poor countries, thus denying the company the opportunity to recoup its investment in R&D by selling the agents in developed countries. 

The report makes the point that pharma companies need to develop a plan to ensure that a country's ability to pay for medications is factored into strategies that companies develop.  From a moral perspective, Oxfam points out, we can no longer ignore this consideration. 

Richard Vanderveer is group CEO, GfK US Healthcare Companies

You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.